Solid-state NMR spectroscopy is an effective technique for the analysis of both crystalline and amorphous pharmaceuticals, both in the drug substance and drug product. In this article, Eric Munson provides an overview of the technique and how it applies to pharmaceutical analysis.
CHARACTERISATION of drug substances and products is critical in the pharmaceutical industry. Solid-state NMR spectroscopy (SSNMR) is an excellent analytical technique used to characterise the solid forms of a drug substance, identify different crystalline structures, monitor form conversion during active pharmaceutical ingredient (API) scale up, detect low amounts of other forms (eg, crystalline in amorphous), measure relaxation times for prediction of physicochemical stability and guard intellectual property. Similarly, drug product is uniquely suited to characterisation by SSNMR because excipients typically do not significantly interfere with the analysis, even at low levels of drug substance in the drug product.
Are you looking to explore how lipid formulations in softgels can enhance drug absorption and bioavailability. Register for our upcoming webinar to find out!
3 September 2025 | 3:00 PM BST | FREE Webinar
This webinar will delve into the different types of lipid formulations, such as solutions, suspensions, emulsions, and self-(micro)emulsifying systems. Applications span diverse therapeutic areas including HIV therapy, oncology, immunosuppressants, and emerging treatments like medicinal cannabis (eg, CBD).
What You’ll Learn:
Lipid formulation development and screening tools for optimisation
Key steps in scale-up and industrialisation to ensure consistency and efficiency
Impact of lipid-based softgels on drug delivery and patient outcomes.
Can’t attend live? No worries – register to receive the recording post-event.
The need for characterisation of drug forms
The physical state of a drug substance and its potential interactions with components in a drug product play a critical role in drug delivery. For example, different solid forms, eg, polymorphs, solvates and amorphous forms, can dramatically impact the amount of drug available to the body (bioavailability) and the ability to successfully make a drug product (manufacturability) by altering physicochemical properties such as solubility and morphology. In many cases, the ability to identify the most stable crystalline form in an API within a drug product is critical to prevent conversion from one crystalline form to another, which could impact the performance of the drug product. Most pharmaceutical companies conduct a series of screening tests to determine both the most stable crystalline form, as well as any potential polymorphic or solvated forms of the API. In many cases, it can be quite difficult to isolate the individual forms that may be found in the API and the drug product.
Regulatory agencies have issued guidance on polymorphism for the development of both new and generic drugs. The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) has adopted guideline Q6A for identifying when polymorphism should be controlled and monitored. In addition, the US Food and Drug Administration (FDA) has issued guidance describing when polymorphism must be addressed in drug substances and drug products in abbreviated new drug applications (ANDAs). This is particularly important when a change of form can impact the bioavailability of the drug. In both the ICH and FDA guidance documents, SSNMR spectroscopy is highlighted as a technique for determining whether multiple polymorphic forms are present.
Why SSNMR spectroscopy?
SSNMR spectroscopy is a particularly powerful technique for the investigation of multiple crystalline forms in both an API and drug product. The benefits of SSNMR spectroscopy include:
it is complementary to powder X-ray diffraction for identifying different crystalline forms
it is the only commonly-used analytical technique that can quantify the amount of each form without the need for a standard
it can detect and quantify the amount of crystalline and amorphous content in an API
it can identify the amount of crystalline and amorphous content for each component in a formulated product
multiple nuclei can be analysed, providing several unique spectra for each form
relaxation times can be used to identify peaks for different crystalline forms, as each relaxation time for a form is usually unique
relaxation times can be used to selectively enhance or remove different forms in a mixture of components, which can be useful for form identification and showing intellectual property infringement
selective labeling of nuclei such as 13C and 15N can be used to enhance certain signals when sensitivity is a challenge, as well as avoiding peak overlap
relaxation times can be used to identify particle size and predict chemical degradation rates, especially in formulated products.
Detecting polymorphs using SSNMR spectroscopy
SSNMR spectroscopy has several advantages for studying polymorphism in pharmaceuticals, including the fact that there are typically several NMR active nuclei that can be studied and each can provide unique information about the sample. The most commonly studied nuclei for identifying multiple crystalline forms in both a drug substance and drug product are 13C and 19F, with lesser studied nuclei including 15N, 31P, 23Na, 35Cl and others.
Figure 1: 13C solid-state NMR (SSNMR) spectra of aspirin, paracetamol and ibuprofen (Advil).
Active pharmaceutical ingredient (API) peaks are indicated by a star (*).
For 13C, there are typically between 10 to 30 peaks in the NMR spectrum for an averagesize pharmaceutical compound that can be used to identify the particular crystalline form being studied. One advantage of 13C SSNMR compared to other analytical techniques such as powder X-ray diffraction is that the peaks for the excipients tend to be between 60 to 110ppm, whereas drugs will tend to have peaks between 0 to 50ppm and 110 to 200ppm. This is highlighted in Figure 1, which shows the 13C SSNMR spectra of aspirin, acetaminophen (paracetamol) and ibuprofen in their respective formulations. The API peaks are indicated by a star. This example shows that many drug peaks do not overlap with excipients and can be used to identify the particular crystalline form.
In 19F SSNMR, the only peaks in the spectrum are due to drug substance, because no excipients contain fluorine. Figure 2 shows the 19F spectra of polymorphs A and B of triamcinolone. Although the bottom spectrum is five percent w/w in a formulation, the only obvious difference between this and the API spectrum (middle) is the scaling factor used to make both spectra a similar intensity.
SSNMR spectroscopy can also provide information about the number of crystallographically inequivalent sites in the crystal lattice. In particular, for 13C SSNMR the presence of two peaks for a specific carbon usually indicates that there are two different conformations/ arrangements of molecules in the asymmetric unit. Likewise, there could be three or four peaks for each carbon, corresponding to that number of molecules in the asymmetric unit. In Figure 2, there are two peaks in the 19F spectrum for each polymorphic form due to two crystallographically inequivalent molecules in the crystal lattice.
Figure 2: 19F solid-state NMR (SSNMR) spectra of triamcinolone API polymorph B (red), a mixture of API polymorph A and B (blue) and the same mixture in a formulation with five percent w/w API.
Quantitation and limit of detection in SSNMR spectroscopy of polymorphs
One of the benefits of SSNMR spectroscopy is that, unlike most other analytical techniques, it is an inherently quantitative technique. In NMR spectroscopy, the response function of each nucleus in the molecule in theory should be the same. This means that the integration of the peaks in an NMR spectrum reflect the amount of each form that is present in the sample. This assumes that the spectra were acquired using quantitative conditions. In most other analytical techniques, a calibration curve has to be prepared, because the response function of the instrument, whether it be the extinction coefficient in optical spectroscopy, such as UV-Vis spectroscopy, or the peak intensity in a powder X-ray diffraction pattern, which could depend upon factors such as preferred orientation or particle size affects, is unknown. In most analytical methodologies, including NMR spectroscopy, the signal-to-noise ratio of 3:1 is often used to determine the limit of detection (LOD) and a signal-to-noise ratio of 10:1 is often used to determine the limit of quantification (LOQ).
LOD and LOQ for polymorphs for SSNMR spectroscopy can vary significantly depending upon line widths, relaxation times and compound molecular weight. In general, LOD of 0.1-1 percent are easily achievable for drug substances that have molecular weights of around 400g/mol, line widths of 0.5ppm or less and 1H T1 relaxation times of 10 seconds or less, which are typical of many drug substances. Low LOD and LOQ are often limited in drug substances by the ability to resolve the different form peaks in the spectrum. If the forms have different relaxation properties, then experiments that can reduce or remove one component selectively can be used to observe the desired component. The detection limits are absolute in that low-dose drug products, eg one to five percent of drug substance by weight in a drug product, still have a drug substance detection limit of 0.1-1 percent, but being able to resolve the different forms is less of a problem.
Amorphous drugs and amorphous solid dispersions
Amorphous solid dispersions (ASD) are being used more frequently in drug products to increase drug bioavailability. An ASD can increase bioavailability several fold, which reduces the pill burden on the patient and may even make a drug candidate viable. One of the challenges of an ASD is that the API is in a metastable state, ie, it would prefer to be in the crystalline state. Since even a small amount of crystalline material could result in decreased bioavailability, regulatory agencies often require monitoring of the drug product for crystallinity. SSNMR spectroscopy is an excellent technique for determining crystallinity in a drug product. For 13C SSNMR, the amorphous peaks are often about an order of magnitude broader than the crystalline peaks. The LOD and LOQ for the crystalline component in an ASD are similar to that of polymorphs, except that the amorphous signal is usually substantially broader than the crystalline signal, making overlap less of an issue compared to a mixture of two crystalline forms. The LOD for an amorphous API is usually substantially higher, often by an order of magnitude compared to the crystalline component, due to line widths that are significantly broader than the crystalline component.
Emerging technologies for SSNMR analysis of pharmaceuticals
SSNMR techniques continue to evolve, expanding both the current detection limits, with the development of cryogenically cooled probes for SSNMR,1 as well as new applications, such as dynamic nuclear polarisation (DNP)2 and time domain (TD) SSNMR.3 In the case of DNP SSNMR, there is the potential to dramatically decrease the detection limits for crystalline forms in drug products, while with TD SSNMR there are potential applications where SSNMR can be used online or at-line in a pharmaceutical manufacturing facility. In these cases, the critical step is to translate the significant capabilities of SSNMR to useful solutions the pharmaceutical industry.
Conclusion
SSNMR spectroscopy is an outstanding technique for the analysis of both crystalline and amorphous pharmaceuticals both in the drug substance and drug product. It is an inherently quantitative technique that can selectively detect the API separately from the excipients. Multiple nuclei can be studied, where each nucleus can provide unique information about the sample. For example, selective labelling of 13C nuclei can be used to both increase sensitivity and isolate signals from a particular functional group, while the 19F SSNMR spectrum only contains signals from the API and not the excipients. Moreover, relaxation filters and multidimensional experiments can be used to isolate components and monitor dynamics, respectively. The detection limits for polymorphs are often superior to other analytical techniques and are usually unaffected by the presence of excipients in drug products.
About the author
Eric Munson is currently the Dane O. Kildsig Chair and Head of the Department of Industrial and Physical Pharmacy at Purdue University. His research programme is focused on the characterisation of pharmaceutical solids using a variety of analytical techniques, with an emphasis on solidstate NMR spectroscopy. He received his BA degree from Augustana College in Sioux Falls and his PhD from Texas A&M University. He was also a postdoctoral fellow at the University of California, Berkeley. After working in the Chemistry Department at the University of Minnesota he moved to the Pharmaceutical Chemistry Department at the University of Kansas in 2001, the Pharmaceutical Sciences Department at the University of Kentucky in 2010 and he took up his current role at Purdue University in 2018. Eric is a coinventor on three patents and has published more than 100 research, review and book chapters.
Disclosure
Eric is partial owner of Kansas Analytical Services, a company that provides solidstate NMR services to the pharmaceutical industry. Figures 1 and 2 were prepared using data from Kansas Analytical Services.
References
Alia Hassan et al., Sensitivity Boosts by the CPMAS CryoProbe for Challenging Biological Assemblies, J Magn Reson 2020, 311: 106680
Qing Zhe Ni et al., In Situ Characterization of Pharmaceutical Formulations by Dynamic Nuclear Polarization Enhanced MAS NMR, J Phys Chem B, 2017, 121: 8132
Dirk Stueber and Stefan Jehle, Quantitative Component Analysis of Solid Mixtures by Analyzing Time Domain 1H and 19F T1 Saturation Recovery Curves (qSRC), J Pharm Sci 2017, 106: 1828
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.
Nice Article, In my company NMR is newly installed can you provide more info on NMR spectroscopy.